To Explore the Treatment Effect of Various Commercially Available Statins on Patients With Hyperlipidemia
Completed
- Conditions
- Hyperlipidemias
- Registration Number
- NCT00726362
- Lead Sponsor
- AstraZeneca
- Brief Summary
The primary objective is to survey the efficacy of various commercially available statins (a class of lipid-lowering agents, for example, rosuvastatin, atorvastatin, simvastatin, lovastatin, pravastatin and fluvastatin) under local clinical practice in treating patients with hyperlipidemia. Surveillance data (Lipid Profile) will be collected during course of usual clinical practice or captured upon its availability.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3270
Inclusion Criteria
- patients diagnosed with hyperlipidemia
- Patients who are just starting a statin treatment, who need to switch from current therapy to a statin medication, or who are receiving dosage adjustment of statin as judged by the physicians
- Patients who are willing to participate in this study and who sign an informed consent form
Read More
Exclusion Criteria
- Pregnancy or breast feeding
- Patient are illiterate or unable to fill the questionnaire for any reason
- Patients with contraindications to the use of certain statins as needed prescribed by physicians (as per commercially available statins package insert) including the use of rosuvastatin.
- Any clinical condition which, in the opinion of the attending physician, would not allow safe administration of the study medications
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes on LDL-C, HDL-C, TG, TC 3~6 months
- Secondary Outcome Measures
Name Time Method ratio for treatment-to-goal 3~6 months drug compliance 3~6 months correlation between patient's insight and therapeutic outcome 3~6 months
Trial Locations
- Locations (1)
Research Site
🇨🇳Yun-Lin, Taiwan